• PAVmed subsidiary Lucid Diagnostics won a positive Concert commercial coverage policy for its EsoGuard esophageal DNA test, effective July 2026.
• Policy deems EsoGuard medically necessary for patients meeting American College of Gastroenterology screening criteria for esophageal precancer and cancer.
• Concert flagged EsoGuard as the only esophageal precancer test meeting its coverage criteria; multiple client health plans have adopted the policy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.